Please use this identifier to cite or link to this item:
Title: Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Authors: Michels, Sebastian
Massutí, Bartomeu
Schildhaus, Hans Ulrich
Franklin, Jeremy
Sebastian, Martin
Felip, Enriqueta
Grohé, Christian
Rodriguez-Abreu, Delvys
Abdulla, Diana S.Y.
Bischoff, Helge
Brandts, Christian
Carcereny, Enric
Corral, Jesús
Dingemans, Anne Marie C.
Pereira, Eva
Fassunke, Jana
Fischer, Rieke N.
Gardizi, Masyar
Heukamp, Lukas
Insa, Amelia
Kron, Anna
Menon, Roopika
Persigehl, Thorsten
Reck, Martin
Riedel, Richard
Rothschild, Sacha I.
Scheel, Andreas H.
Scheffler, Matthias
Schmalz, Petra
Smit, Egbert F.
Limburg, Meike
Provencio, Mariano
Karachaliou, Niki
Merkelbach-Bruse, Sabine
Hellmich, Martin
Nogova, Lucia
Büttner, Reinhard
Rosell, Rafael
Wolf, Jürgen
UNESCO Clasification: 320101 Oncología
Keywords: Crizotinib
Lung Cancer
Targeted Treatment
Issue Date: 2019
Journal: Journal of Thoracic Oncology 
Abstract: Introduction: ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been shown in early phase trials in the United States and East Asia. Here we present data on efficacy and safety of a prospective phase II trial evaluating crizotinib in European ROS1-positive patients (EUCROSS). Patients and Methods: The trial was a multicenter, single-arm phase II trial ( identifier: NCT02183870). Key eligibility criteria included patients who were 18 years of age or older with advanced/metastatic lung cancer and centrally confirmed ROS1-rearranged lung cancer (fluorescence-in situ hybridization). Treatment included 250 mg crizotinib twice daily. The primary endpoint was investigator-assessed objective response rate (ORR) (Response Evaluation Criteria in Solid Tumors, version 1.1). Key secondary endpoints were progression-free survival (PFS), overall survival, efficacy by independent radiologic review, safety, health-related quality of life, and molecular characterization of tumor tissue. Results: Thirty-four patients received treatment. Four patients were excluded from efficacy analysis. Investigator ORR was 70% (95% confidence interval [CI]: 51–85; 21 of 30 patients) and median PFS was 20.0 months (95% CI: 10.1–not reached). Two patients with ROS1 wild-type sequences assessed by DNA sequencing had progression as best response. CD74-ROS1-positive patients had a trend towards a higher ORR and longer median PFS. TP53-co-mutant patients had a significantly shorter median PFS than wild-type patients (7.0 months, 95% CI: 1.7–20.0 versus 24.1 months, 95% CI: 10.1–not reached; p = 0.022). Treatment-related adverse events were documented in 33 of 34 patients (97%). Conclusions: Crizotinib is highly effective and safe in patients with ROS1-rearranged lung cancer. ROS1-/TP53-co-aberrant patients had a significantly worse outcome compared to TP53 wild-type patients.
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2019.03.020
Source: Journal of Thoracic Oncology [ISSN 1556-0864],v. 14 (7), p. 1266-1276
Appears in Collections:Artículos
Adobe PDF (686,48 kB)
Show full item record


checked on Jun 20, 2021


checked on Jun 20, 2021

Page view(s)

checked on Jun 22, 2021


checked on Jun 22, 2021

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.